Le Lézard
Classified in: Science and technology
Subjects: Product/Service, Survey

92% of CISOs Question the Future of Their Role Amidst Growing AI Pressures


RSAC 2024 -- Trellix, the cybersecurity company delivering the future of extended detection and response (XDR), today announced a new report, Mind of the CISO: Decoding the GenAI Impact, launched in partnership with leading bipartisan research organization and think tank, the Center for Strategic and International Studies (CSIS). The research reveals insights from a survey of 500 security executives in North America on how increasing GenAI and AI use is currently evolving the threat landscape and the CISO role to reshape the future of cybersecurity in the workplace.

"GenAI and AI have the potential to both disrupt and enhance security operations. As the acting gatekeepers - CISOs are under immense pressure," said Harold Rivas, CISO, Trellix. "The CISO role is vital to the organization's health. Navigating how to embrace AI while supporting the professionals leading our cyber defenses is mission-critical for all organizations and national security."

The democratization of GenAI means it can be used by professionals at every skill level, bringing with it a range of benefits as well as potential risks and challenges. This same democratization makes GenAI capabilities easy to access and economical for malicious cyber actors. The role of the CISO has become even more essential as they're looked upon to navigate this evolving landscape. With cyberattacks on the rise, AI pressures mounting, and responsibilities growing, it's no surprise 90% of CISOs find themselves under increased pressure. Keeping pace with AI and GenAI is vital, and almost all respondents said their organizations could do more.

Increased risk is balanced with the recognized potential for GenAI to better strengthen and prepare their own cybersecurity measures, with 91% of CISOs expressing excitement over the prospects and opportunities. Paving the way for success, almost half of CISOs surveyed are already working to secure their AI tools, with 45% developing an AI committee to review AI tools as well as implementing governance, including security frameworks and standards.

Notable CISO insights shed light on the challenges along with the solutions GenAI and AI present in security operations:

"CISOs' concerns over shifting AI regulations have them asking policymakers for greater regulation around its use, with nearly all agreeing it's needed in the next six months," said James Lewis, SVP, Pritzker Chair, and Director, Strategic Technologies Program, CSIS. "This isn't surprising given the inherent risks and current potential for increased exposure and liability in their role. There needs to be clear regulatory rules and compliance standards applicable across industries to help enable CISOs and their organizations to develop scalable solutions for global adoption."

Learn more about Mind of the CISO: Decoding the GenAI Impact here. Additional insights will be shared in a live and virtual event hosted by Trellix and CSIS on Thursday, May 16, 1 - 2 PM ET.

Trellix's Mind of the CISO initiative was launched last year to bring global attention to the needs of the CISO community, driving cybersecurity and AI best practices. Trellix continuously looks to support the global CISO community by engaging, listening, and advocating.

Additional Resources:

Methodology
Trellix commissioned independent market research agency Vanson Bourne to conduct a survey of 500 CISOs across North America to understand their perceived risks and benefits for using GenAI within security operations at their organizations. Respondents work across various industries, including finance, public sector, healthcare (public and private), manufacturing, energy, oil, gas, and utilities. Most CISOs surveyed (76%) already use GenAI in their organizations, with most of the remaining 24% planning to, and 70% of CISOs currently use traditional AI, with 26% planning to.

About CSIS:
Established in Washington D.C., over 60 years ago, The Center for Strategic and International Studies (CSIS) is a bipartisan, nonprofit policy research organization dedicated to providing strategic insights and policy solutions to help decision makers chart a course toward a better world. More at CSIS | Center for Strategic and International Studies.

About Trellix
Trellix is a global company redefining the future of cybersecurity and soulful work. The company's open and native extended detection and response (XDR) platform helps organizations confronted by today's most advanced threats gain confidence in the protection and resilience of their operations. Trellix, along with an extensive partner ecosystem, accelerates technology innovation through artificial intelligence, automation, and analytics to empower over 40,000 business and government customers with living security. More at https://trellix.com.

Follow Trellix on LinkedIn and X.


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: